Renaissance Capital logo

Denali Therapeutics Priced, Nasdaq: DNLI

Early-stage biotech developing novel therapies for neurodegenerative diseases.

Industry: Health Care

First Day Return: +19.2%

Our goal is to discover and develop therapeutics to defeat degeneration. We have a focused yet diversified portfolio that currently consists of six core and five seed programs. Our most advanced program targets LRRK2 for the treatment of Parkinson's disease and has a product candidate currently in Phase 1 development. Our next most advanced program targets RIPK1 for the treatment of Alzheimer's disease and ALS and current has a product candidate in IND-enabling studies with an IND or CTA filing planned for early 2018. In addition, we have four core programs in preclinical development that use our proprietary blood-brain barrier (BBB) platform technology.

Denali Therapeutics (DNLI) Performance

Created with Highcharts 10.3.2Chart context menuDNLI vs. IPO Index (IPOUSA)Jan 2018Jan 20…Jul 2018Jan 2019Jul 2019Jan 2020Jul 2020Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 20250%+ 100%+ 200%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index